Table 1.
Underlying diseases and demographic characteristics of the study cohort.
| Underlying disease | Study population N (%) | Age at vaccination Years, median (IQR) | M/F (% M) | Days from 2nd Vx to serology median (IQR) |
|---|---|---|---|---|
| All patients | 1002 | 63.0 (51.0–72.0) | 654/348 (65.3) | 19.0 (14.0–25.0) |
| CLL/NHL | 188 (18.8) | 69.0 (61.0–74.0) | 102/86 (54.3) | 18.0 (15.0–27.0) |
| Multiple myeloma | 187 (18.7) | 66.0 (59.0–73.0) | 117/70 (62.6) | 18.0 (15.0–23.0) |
| HIV | 156 (15.6) | 49.0 (42.0–57.0) | 137/19 (87.8) | 19.0 (14.0–21.0) |
| HSCT | 111 (11.1) | 62.0 (49.0–70.0) | 70/41 (63.1) | 21.0 (17.0–28.0) |
| Kidney transplant | 111 (11.1) | 60.0 (49.0–70.0) | 88/23 (79.3) | 22.0 (15.0–33.0) |
| Solid malignancies | 90 (9) | 64.0 (53.0–73.0) | 44/45 (49.4) | 15.0 (12.0–20.0) |
| Heart transplant | 80 (8) | 61.5 (50.0–68.0) | 55/25 (68.8) | 15.0 (14.0–26.5) |
| Myelodysplastic disorders | 43 (4.3) | 73.0 (66.0–80.0) | 22/21 (51.2) | 26.0 (17.0–35.0) |
| Liver transplant | 36 (3.6) | 68.0 (51.0–71.0) | 19/17 (52.8) | 15.0 (13.0–26.5) |
| Control after 2nd dose | 272 | 57.0 (44.0–67.0) | 66/206 (24.3) | 26.0 (24.0–27.0) |
SD – standard deviation, M/F – males/females, Vx – vaccination, CLL - chronic lymphocytic leukemia, NHL - non-Hodgkin's lymphoma, HIV-human immunodeficiency virus, HSCT - hematopoietic stem cell transplantation.